Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | BTK | Q06187 | 2/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342773 | 1.00 | CA1 (0.62) | CA1CA2CTSKBTKJAK3 | |
| SCHEMBL20184622 | 1.00 | CA1 (0.62) | CA1CA2CTSKBTKJAK3 | |
| SCHEMBL26091580 | 0.96 | CA1 (0.57) | CA1CA2CTSKBTKJAK3 | |
| SCHEMBL3544236 | 0.91 | CTSK (0.59) | CA1CA2CTSKBTKCYP2C9 | |
| SCHEMBL12321230 | 0.91 | CTSK (0.59) | CA1CA2CTSKBTKCYP2C9 | |
| SCHEMBL3942865 | 0.91 | CTSK (0.59) | CA1CA2CTSKBTKCYP2C9 | |
| SCHEMBL21733136 | 0.89 | CA1 (0.56) | CA1CA2CTSKBTKJAK3 | |
| SCHEMBL29255478 | 0.89 | CA1 (0.56) | CA1CA2CTSKBTKJAK3 | |
| SCHEMBL29276213 | 0.86 | CA1 (0.56) | CA1CA2CTSKBTKJAK3 | |
| SCHEMBL28673367 | 0.86 | CA1 (0.56) | CA1CA2CTSKBTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655287-A2 | INHIBITORS OF NLRP3 | MWYNGIL THERAPEUTICS, INC. (US) | 2025-12-03 | — | — | EP | disclosed |
| CN-119212699-A | NLRP3 inhibitors | PTC医疗公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4479045-A2 | INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-20240262806-A1 | INHIBITORS OF NLRP3 | PCT THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| WO-2024158941-A2 | INHIBITORS OF NLRP3 | MWYNGIL THERAPEUTICS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| US-20240254132-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TENVIE THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4392414-A1 | INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-118119626-A | Fused bicyclic heteroaryl compounds useful as NLRP3 inhibitors | 豪夫迈·罗氏有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4370110-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| EP-4196125-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| CN-116261456-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4157823-A1 | COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-04-05 | — | — | EP | disclosed |
| WO-2023028534-A1 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023028534-A1 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023288039-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022036204-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2021239885-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | WO | disclosed |
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | CA1 4057/4885CA2 2830/4885CTSK 767/4885 |
| US-20240262806-A1 | INHIBITORS OF NLRP3 | NLRP3, NOD1, NLRP1 | CA1 4703/4885CA2 3427/4885CTSK 878/4885 |
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | CA1 1531/4885CA2 138/4885CTSK 3757/4885 |
| US-20240254132-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | NLRP3, NLRP1, NOD1 | CA1 3514/4885CA2 3657/4885CTSK 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.